Clinical trial NCT00368329: Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
Official title: Phase I Study of Dose Escalation Using Image-guided Radiotherapy to Deliver a Stereotactic Radiosurgical Boost After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Esophageal Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Esophageal Neoplasms
Carcinoma, Squamous Cell
Adenocarcinoma
Esophageal Cancer
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2006-08-24
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To study the safety and feasibility of stereotactic radiation dose escalation following neoadjuvant chemotherapy with concurrent conventionally fractionated radiation, by evaluating the acute and late toxicity of treatment.

Detailed description: This study will evaluate the safety and feasibility of delivering radiation dose escalation using hypofractionated radiosurgery in locally advanced esophageal cancer. The dose escalation will be delivered using an image-guided radiosurgical boost to the tumor volume, following a neoadjuvant regimen consisting of oxaliplatin, capecitabine, and conventionally fractionated radiotherapy. In addition, we will evaluate the utility of PET-FDG before and after neoadjuvant chemoradiation in predicting the pathologic response to pre-operative treatment. We will study the effect of this regimen on pathologic complete response rates and complete resection rates at surgery among patients with locally advanced esophageal cancer and determine patterns of failure and rates of progression-free survival. Finally, we plan to characterize in an exploratory manner the correlation between molecular markers and pathologic findings following pre-operative chemoradiation.

Eligibility criteria: Inclusion Criteria:- Confirmed diagnosis of adenocarcinoma or squamous cell carcinoma of the esophagus by pathologist.

* Endoscopic ultrasound or CT evidence of tumor penetration through the esophageal wall or involvement of regional lymph nodes, without evidence of distant metastasis
* No prior chest radiation therapy
* No prior chemotherapy for esophageal cancer
* Age greater than 18 years
* No infections requiring antibiotic treatment
* Able to care for self
* Patients must have acceptable liver, kidney and bone marrow function.
* The effects of the chemotherapy drugs on the developing human fetus are unknown. Women of child-bearing potential and men must agree to use adequate contraception. Exclusion Criteria:- Patients receiving any other investigational agents
* Evidence of distant metastases
* Uncontrolled medical illness
* Any malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix.
* Pregnant and breastfeeding women are excluded.
* HIV-positive patients

Primary outcomes:
measure: A complete assessment of all pathologic specimens (biopsy and definitive surgical) to document the histology, grade, depth of invasion, lymphovascular or perineural invasion.
measure: The inked margins on the definitive surgical specimen will be inked and margin status, size of the tumor, evidence of residual tumor will be recorded.
measure: Patients' responses to therapy will be evaluated clinically after completion of their neoadjuvant chemoradiation.
timeFrame: after completion of their neoadjuvant chemoradiation
Secondary outcomes:
measure: Physical exam
timeFrame: Once every three months for two years, then every six months for three years and then once a year.
measure: CT scan
timeFrame: Three months after completion of therapy, then every six months for three years then once a year for until 5 years from completion of therapy.
measure: Upper endoscopy
timeFrame: Three months after completion of therapy, then every six months for three years then once a year for until 5 years from completion of therapy.
measure: Patterns of failure and the 2-year progression-free survival (PFS) rate.
timeFrame: 2 years
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Daniel T Chang
role: PRINCIPAL_INVESTIGATOR
References: